A Phase 1/2 interventional study of GD2 CAR-T immunotherapy in Glioma of Brain and CAR-T Cell Immunotherapy, sponsored by Fuda Cancer Hospital, Guangzhou. Withdrawn. Open to participants aged 30 Years to 70 Years. Per ClinicalTrials.gov, last updated 2020-07-16.
Sponsored by Fuda Cancer Hospital, Guangzhou · Phase 1/2, Interventional, and Treatment
The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in treating with GD2 positive glioma patients.
Chimeric antigen receptor (CAR) is a recombinant receptor with both antigen-binding and T cell activating functions. Chimeric antigen receptor T cell Immunotherapy has more advantages compared with conventional immunotherapy, especially in dealing with patients of hematologic malignancies and solid malignant tumors.This study design a novel specific Chimeric antigen receptor aiming at GD2 antigen.After CAR-T cell infusion,At periodic intervals, the investigators will evaluate clinical symptoms Improved conditions of this disease.Through this study,the investigators will evaluate the safty and effectiveness of CAR-T cell immunotherapy in treating with GD2 positive glioma patients.
1,397 studies on the registry are indexed under Glioma; 351 are open to participants now.
Browse Glioma studies →Fuda Cancer Hospital, Guangzhou is the lead sponsor of 113 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Treated by GD2 CAR-T therapy intravenously
Biological: GD2 CAR-T immunotherapy
With no medical intervention
Antigen-specific T cell therapy
Also known as: CAR-T for glioma
Classification of adverse reactions
To observe the common 1-4 levels of side effects
Time frame: 3 months
Progression free survival （PFS）of patients
PFS was defined as the interval between treatment initiation and local relapse, distant metastasis, or death, whichever occurred first.
Time frame: 1 year
No study locations are listed for this record.
This study is withdrawn, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fuda Cancer Hospital, Guangzhou